Initial Treatment for Anti-68kD Antibody-Positive Dermatomyositis

Understanding Anti-68kD Antibodies

The presence of anti-68kD antibodies in dermatomyositis patients indicates a specific type of myositis-associated autoantibody, with treatment principles applying from idiopathic inflammatory myositis 2, 3

The American College of Rheumatology recommends starting oral prednisone at 1-2 mg/kg/day (typically 60-80 mg daily) for adult patients with active myositis, with a tapering schedule after 2-4 weeks of clinical improvement 1, 4
For severe presentations, consider intravenous methylprednisolone 10-20 mg/kg or 250-1000 mg for 1-5 consecutive days before transitioning to oral therapy 4
Methotrexate 15-20 mg/m² weekly via subcutaneous route should be initiated at treatment onset, as it provides superior absorption compared to oral dosing 1

Baseline cardiac evaluation, including troponin I and electrocardiography, is mandatory before initiating treatment, as myocarditis occurs in approximately 20% of checkpoint inhibitor-related myositis cases 2, 3
If troponin is elevated or clinical symptoms suggest cardiac involvement, obtain cardiac MRI immediately 2
Normal cardiac enzymes do not completely exclude myocarditis 2

Assess clinical response at 12 weeks by monitoring muscle strength, CK levels, and inflammatory markers, and verify medication adherence and tolerance before escalating therapy 1
MRI with T1-weighted, T2-weighted, and fat suppression sequences can monitor treatment response objectively 4, 5

For methotrexate intolerance, switch to mycophenolate mofetil or cyclosporine A, and consider adding intravenous immunoglobulin (IVIG) for inadequate response despite adherence 1
Plasma exchange may be considered in severe, refractory cases 3, 2

Sun protection, calcium and vitamin D supplementation, and PCP prophylaxis are essential supportive measures to prevent photosensitive rash exacerbations, corticosteroid-induced osteoporosis, and infections 1, 6
A supervised physiotherapy program should be implemented to restore muscle strength during remission phase, not during active inflammation 1